Consensus Guidelines from the American Society of Pain and Neuroscience for the Use of 60-Day Peripheral Nerve Stimulation Therapy. A NEURON Living Guideline Project
- PMID: 40590046
- PMCID: PMC12206896
- DOI: 10.2147/JPR.S521788
Consensus Guidelines from the American Society of Pain and Neuroscience for the Use of 60-Day Peripheral Nerve Stimulation Therapy. A NEURON Living Guideline Project
Abstract
Peripheral nerve stimulation (PNS) has evolved with various applications and durations of therapy. In recent years, extensive data has been developed on a 60-day treatment using a novel approach. Confusion exists on the use of a trial therapy, a permanent implant, and a 60-day duration treatment. The American Society of Pain and Neuroscience (ASPN) seeks to clarify the literature associated with this neuromodulation approach. A diverse group of experts was nominated to provide opinions and guidance based on evidence-graded assessment and clinical knowledge. This guidance is the first to specifically assess the clinical use of 60-day PNS and best medical practice.
Keywords: best practices; clinical guidelines; pain medicine; peripheral nerve stimulation.
© 2025 Gill et al.
Conflict of interest statement
Usman Latif: Consultant: Abbott, Brixton Biosciences, Hydrocision, Nalu Medical, Nevro, Omnia Medical, Saluda, Spinal Simplicity, SPR Therapeutics, Stryker, Vertos Medical, Vivex Biologics; Research funding: Mainstay Medical, Spinal Simplicity, Vivex Biologics; Stock: InFormed Consent, Spinal Simplicity. Scott Pritzlaff: Consultant SPR Therapeutics, Bioventus, Nalu Medical; Education grants from Abbott, Biotronik, Medtronic, and Nevro; Royalties from Wolters Kluwer. Ioannis Skaribas: Consultant Abbott, Nalu. Hemant Kalia: Consultant Abbott, Averitas, Nalu, Curonix, SPR Therapeutics, Nervonik, Virdio Health. Samir Sheth: Consultant SPR, Medtronic, Vertos, Boston Scientific, SI Bone; Royalties from Wolters Kluwer. Madi Schnur: Consultant SPR Therapeutics. Sean Li: Consultant Abbott, Avanos, Averitas Pharma, Boston Scientific, Biotronik, Medtronic, Nalu Medical, PainTeq, Presidio, Saluda, SPR Therapeutics, Stryker; Research funding Avanos, Averitas Pharma, Nevro, Presidio, SPR Therapeutics, Stock options NeuroOne, Nalu Medical. Denise Lester: the Primary Investigator for the RESET trial; Research funding from SPR Therapeutics. Ramana Naidu: Consultant Abbott, Avanos, Boston Scientific, Bioventus, Biotronik, Medtronic, Nalu Medical, Nervonik, SPR Therapeutics. Royalties from McGraw-Hill. David Russo: Consultant Nalu, Nevro. Einar Ottestad: Consultant for BioVentus, SPR Therapeutics, Coloplast; Stock options for Restera Medical; Co-founder Altamont Medical. Henry Vucetic: Consultant Abbott, SPR Therapeutics, Vertos, Saluda, Boston Scientific. David Abejón: Proctor Abbott, Medtronic, Boston Scientific, Cardiva, MBA, Saluda Medical. Mehul Desai: Consultant Medtronic, Nalu Medical Stock Options AllaiHealth, HypreVention, SPR Therapeutics, SynerFuse, Virdio Health, Royalties Oxford Medical. David Dickerson: Consultant SPR, Stryker, Nalu, Vertos, Vertex, Abbott, Biotronik; Research support Abbott, SPR. Amitabh Gulati: Consultant for SPR therapeutics, Nalu Medical, Medtronic, AIS healthcare, Neurovasis, Tersera Medical, Hinge Health, Menda Health, Veritas Pharma. Sayed Dawood: Stock Options Spr, Painteq, Mainstay; personal fees from Abbott, Saluda. Timothy Deer: consultant research Abbott, SpineThera, Saluda Medical, Cornerloc, Boston Scientific, personal fees, Pain Teq, Spinal Simplicity, Biotronik, Aurora, Nervonik, SPR Therapeutics, outside the submitted work; In addition, Dr Timothy Deer has a patent pending to Abbott. The other authors report no conflicts of interest in this work.
Figures
Similar articles
-
Clinical guidelines and payer policies on fusion for the treatment of chronic low back pain.Spine (Phila Pa 1976). 2011 Oct 1;36(21 Suppl):S144-63. doi: 10.1097/BRS.0b013e31822ef5b4. Spine (Phila Pa 1976). 2011. PMID: 21952186
-
What is the value of routinely testing full blood count, electrolytes and urea, and pulmonary function tests before elective surgery in patients with no apparent clinical indication and in subgroups of patients with common comorbidities: a systematic review of the clinical and cost-effective literature.Health Technol Assess. 2012 Dec;16(50):i-xvi, 1-159. doi: 10.3310/hta16500. Health Technol Assess. 2012. PMID: 23302507 Free PMC article.
-
Single-incision sling operations for urinary incontinence in women.Cochrane Database Syst Rev. 2017 Jul 26;7(7):CD008709. doi: 10.1002/14651858.CD008709.pub3. Cochrane Database Syst Rev. 2017. Update in: Cochrane Database Syst Rev. 2023 Oct 27;10:CD008709. doi: 10.1002/14651858.CD008709.pub4. PMID: 28746980 Free PMC article. Updated.
-
Review of guidelines for good practice in decision-analytic modelling in health technology assessment.Health Technol Assess. 2004 Sep;8(36):iii-iv, ix-xi, 1-158. doi: 10.3310/hta8360. Health Technol Assess. 2004. PMID: 15361314
-
Chemoprevention of breast cancer. A joint guideline from the Canadian Task Force on Preventive Health Care and the Canadian Breast Cancer Initiative's Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer.CMAJ. 2001 Jun 12;164(12):1681-90. CMAJ. 2001. PMID: 11450210 Free PMC article.
References
-
- Gildenberg PL. History of electrical neuromodulation for chronic pain. Pain Med. 2006;7(s1):S7–S13.
LinkOut - more resources
Full Text Sources
